RARichard Anderson

Richard Anderson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Richard Anderson has a total of 153 co-authors. Here are the top co-authors by number of shared publications:

  • Tim Kinnaird

    Department of Cardiology, University Hospital of Wales, Cardiff, United Kingdom

    6 shared publications
  • Sean Gallagher

    Department of Cardiology University Hospital of Wales Cardiff UK

    4 shared publications
  • Alexandra J. Lansky

    Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA

    3 shared publications
  • Andrew S. P. Sharp

    Department of Cardiology University Hospital of Wales Cardiff UK

    3 shared publications
  • Bo Xu

    Department of Cardiology, National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen, Shenzhen, China

    3 shared publications
  • Saqib Chowdhary

    Wythenshawe Hospital, Manchester University Foundation Trust, Manchester, UK

    3 shared publications

Latest Publications

  • Open Access

    Abluminal groove-filled biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent: three-year results of the TARGET All Comers trial

    by Yuichi Saito, Henning Kelbæk, Bo Xu, Yasin Hussain, Richard Anderson, Volker Schächinger, Ming Zheng, William Wijns, Andreas Baumbach, Alexandra J. Lansky

    The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)


  • Open Access

    Vascular complications associated withintraaorticballoon pump supported percutaneous coronary intervention (PCI)and clinical outcomes from the British Cardiovascular Intervention Society NationalPCIDatabase

    by Tim Kinnaird, Richard Anderson, Sean Gallagher, Andrew S. P. Sharp, Vasim Farooq, Peter Ludman, Samuel Copt, Nicholas Curzen, Alex Sirker, Jim Nolan, et al.

    Introduction: The impact of a vascular complication (VC) in the setting of intraaortic balloon pump (IABP) supported PCI on clinical outcomes is unclear.Methods: Using data from the BCIS National PCI Database, multivariate logistic regression was used to identify independent predictors of a VC. Propensity scoring was used to quantify the association between a VC and outcomes.Results: Between 2007 and 2014, 9,970 PCIs in England and Wales were supported by IABP (1.6% of total PCI), with 224 femoral VCs (2.3%). Annualized rates of a VC reduced as the use of radial access for PCI increased. The independent predictors of a VC included a procedural complication (odds ratio [OR] 2.9,p < .001), female sex (OR 2.3,p < .001), PCI for stable angina (OR 3.47,p = .028), and use of a glycoprotein inhibitor (OR 1.46 [1.1:2.5],p = .04), with a lower likelihood of a VC when radial access was used for PCI (OR 0.48,p = .008). A VC was associated with a higher likelihood of transfusion (OR 5.7 [3.5:9.2],p < .0001), acute kidney injury (OR 2.6 [1.2:6.1],p = .027), and periprocedural MI (OR 3.2 [1.5:6.7],p = .002) but not with adjusted mortality at discharge (OR 1.2 [0.8:1.7],p = .394) or 12‐months (OR 1.1 [0.76:1.56],p = .639). In sensitivity analyses, there was a trend towards higher mortality in patients experiencing a VC who underwent PCI for stable angina (OR 4.1 [1.0:16.4],pvalue for interaction .069).Discussion and ConclusionsAlthough in‐hospital morbidity was observed to be adversely affected by occurrence of a VC during IABP‐supported PCI, in‐hospital and 1‐year survival were similar between groups.

  • The impact of coronary perforation in percutaneous interventions involving the left main stem coronary artery in the United Kingdom 2007-2014: Insights from the British Cardiovascular Intervention Society database

    by Hussain I. Hussain, Majd B. Protty, Sean Gallagher, Sara Al‐Raisi, Omar Aldalati, Vasim Farooq, Andrew S. P. Sharp, Richard Anderson, Tim Kinnaird

    Background Percutaneous coronary intervention (PCI) is increasingly utilized for treatment of coronary disease involving the unprotected left main stem (ULMS). However, no studies to date have examined the outcomes of such interventions when complicated by coronary perforation (CP). Methods Using the British Cardiovascular Intervention society (BCIS) database, data were analyzed on all ULMS-PCI procedures complicated by CP in England and Wales between 2007 and 2014. Multivariate logistic regressions were used to identify predictors of ULMS CP and to evaluate the association between this complication and outcomes. Results During 10,373 ULMS-PCI procedures, CP occurred more frequently than in non-ULMS-PCI (0.9 vs. 0.4%, p < .001) with a stable annual incidence. Covariates associated with CP included number of stents used, female gender, use of rotational atherectomy and chronic total occlusion (CTO) intervention. Adjusted odds of adverse outcomes for ULMS-PCI complicated by CP were higher for peri-procedural complications including cardiogenic shock, tamponade, side-branch loss, DC cardioversion, in-hospital major bleeding, transfusion requirement, and peri-procedural myocardial infarction. There were also significantly increased odds for in-hospital major adverse cardiac events (MACCE, OR 8.961, 95% CI [4.902-16.383]) and 30-day mortality (OR 5.301, 95% CI [2.741-10.251]). Conclusions CP is an infrequent event during ULMS-PCI and is predicted by female gender, rotational atherectomy, CTO interventions or number of stents used. CP was associated with significantly higher odds of mortality and morbidity, but at rates similar to previously published all-comer PCI complicated by CP.


  • Differential impact of abluminal groove‐filled biodegradable‐polymer sirolimus‐eluting stent versus durable‐polymer everolimus‐eluting stent on and off dual antiplatelet therapy

    by Yuichi Saito, William Wijns, Andreas Baumbach, Bo Xu, Henning Kelbæk, Ming Zheng, Marie‐Angèle Morel, Richard Anderson, Volker Schächinger, Alexandra Lansky, et al.

    Background Current guidelines recommend dual antiplatelet therapy (DAPT) following percutaneous coronary intervention for 6–12 months in patients with acute coronary syndrome (ACS) and 3–6 months in those with chronic coronary syndromes (CCS). Whether DAPT duration has a differential effect on outcomes following treatment of ischemic coronary disease with durable versus biodegradable drug‐eluting stent (DES) is poorly defined. Methods The TARGET All Comer study was a randomized trial of patients with ischemic coronary artery disease assigned to treatment with either a biodegradable polymer DES (Firehawk) or a durable polymer DES (XIENCE). This pre‐specified TARGET AC sub‐analysis sought to evaluate the 2‐year clinical outcomes before and after DAPT discontinuation. The primary endpoint was target lesion failure (TLF). Results A total of 1,296 (78.4%) of 1,653 randomized patients were included in this substudy, of which 1,210 (93.4%) remained on DAPT at 6 months, 863 (66.6%) at 12 months, and 409 (31.6%) at 2 years. There was no difference in TLF between patients treated with Firehawk and XIENCE stents from index procedure to DAPT discontinuation (8.0 and 7.7%, p > .99) or after DAPT discontinuation (2.9 vs. 3.8%, p = .16). After DAPT discontinuation, target vessel myocardial infarction (1.3 vs. 3.3%, p = .07), and ischemia‐driven target lesion revascularization (0.5 vs. 1.9%, p = .06) favored treatment with Firehawk. Conclusions Although TLF was comparable for both Firehawk and XIENCE stent groups before and after DAPT discontinuation, after DAPT discontinuation, there was a trend for less target vessel myocardial infarction and ischemia‐driven revascularization with the biodegradable polymer DES.


  • Open Access

    Short- and medium-term survival after TAVI: Clinical predictors and the role of the FRANCE-2 score

    by Zong Xuan Lee, Senthil Elangovan, Richard Anderson, Peter Groves


  • Excimer laser coronary atherectomy during complex PCI: An analysis of 1,471 laser cases from the British Cardiovascular Intervention Society database

    by Majd B. Protty, Hussain I. Hussain, Sean Gallagher, Sara Al‐Raisi, Omar Aldalati, Vasim Farooq, Andrew S. P. Sharp, Mohaned Egred, Peter O'Kane, Peter Ludman, et al.

    Introduction Excimer laser coronary atherectomy (ELCA) is a recognized adjunctive therapy utilized in the percutaneous management of complex coronary lesions. Studies examining its safety and utility have been limited by small sample sizes. Our study examines the determinants and outcomes of ELCA. Methods Using the British Cardiac Intervention Society database, data were analyzed on all PCI procedures in the UK between 2006–2016. Descriptive statistics and multivariate logistic regressions were used to examine baseline, procedural and outcome associations with ELCA. Results We identified 1,471 (0.21%) ELCA cases out of 686,358 PCI procedures. Baseline covariates associated with ELCA use were age, BMI, number of lesions, CTO or restenosis attempted and history of prior MI, CABG or PCI. Procedural co‐variates associated with ELCA were the use of glycoprotein inhibitors, intravascular imaging, rotational atherectomy, cutting balloons, microcatheters and intra‐aortic balloon pumps. Adjusted rates of in‐hospital major adverse cardiac/cerebrovascular events (MACCE) or its individual components (death, peri‐procedural MI, stroke and major bleed) were not significantly altered by the use of ELCA. However, there were higher odds of dissection (OR 1.52, 95% CI 1.17–1.98), perforation (OR 2.18, 95% CI 1.44–3.30), slow flow (OR: 1.67, 95% CI 1.18–2.36), reintervention (OR: 2.12, 95% CI 1.14–3.93) and arterial complications (OR: 1.63, 95% CI 1.21–2.21). Conclusions ELCA use during complex PCI is associated with higher risk baseline and procedural characteristics. Although increased rates of acute procedural complications were observed, ELCA does not increase likelihood of in‐hospital MACCE or its individual components.


  • Management of stent underexpansion using intravascular lithotripsy—Defining the utility of a novel device

    by Julian Yeoh, Daan Cottens, Claudia Cosgrove, Khaled Mallek, Julian Strange, Richard Anderson, Simon Wilson, Colm Hanratty, Simon Walsh, Margaret McEntegart, et al.

    Objectives: This study aimed to present a case series of patient treated for stent underexpansion resistant to conventional treatment with intravascular lithotripsy (IVL).Background: Stent underexpansion is a powerful predictor of long‐term stent patency and correlates with unfavorable clinical outcomes. This case series demonstrates the utility of IVL in managing stent underexpansion resistant to conventional treatment.Methods: We describe a case series of patients with stent underexpansion due to calcific coronary artery disease treated with IVL. Stent underexpansion was identified as an inability to adequately expand stents with conventional treatment. Only cases that failed to achieve adequate expansion with high‐pressure noncompliant balloon inflation were included.Results: Thirteen patients from six institutions have been included in this case series. The average age was 70.25 years with 76.9% of male patients. The average pre‐IVL minimal stent area (MSA) was 2.71 mm2, which improved to 6.44 mm2 post‐IVL treatment, representing an average MSA gain of 238%. There were no procedural, peri‐procedural, or 30‐day major adverse cardiac and cerebrovascular event.Conclusion: This case series demonstrates that IVL is a feasible, safe alternative for the management of stent underexpansion due to calcific coronary disease.


  • Impact of established cardiovascular disease on outcomes in the randomized global leaders trial

    by Scot Garg, Ply Chichareon, Norihiro Kogame, Kuniaki Takahashi, Rodrigo Modolo, Chun‐Chin Chang, Mariusz Tomaniak, Farzin Fath‐Ordoubadi, Richard Anderson, Keith G. Oldroyd, et al.

    Objective: To investigate the impact of different anti‐platelet strategies on outcomes after percutaneous coronary intervention (PCI) in patients with established cardiovascular disease (CVD).Methods: GLOBAL LEADERS was a randomized, superiority, all‐comers trial comparing one‐month dual anti‐platelet therapy (DAPT) with ticagrelor and aspirin followed by 23‐month ticagrelor monotherapy (experimental treatment) with standard 12‐month DAPT followed by 12‐month aspirin monotherapy (reference treatment) in patients treated with a biolimus A9‐eluting stent. Established CVD was defined as ≥1 prior myocardial infarction, PCI, coronary artery bypass operation, stroke, or established peripheral vascular disease. The primary endpoint was a composite of all‐cause death or new Q‐wave MI at 2‐years. The secondary safety endpoint was BARC 3 or 5 bleeding. Exploratory secondary endpoints were the patient‐orientated composite endpoint and net adverse clinical events.Results: Among the 15,761 patients in this cohort were 6,693 patients (42.5%) with established CVD. Compared to those without established CVD, these patients had significantly higher rates of the primary (5.1 vs. 3.3%, HR1.59[1.36–1.86], p < .001) and secondary composite endpoints with no significant differences in bleeding. There was a nonsignificant reduction in the primary endpoint in patients with established CVD receiving the experimental treatment (4.6 vs. 5.6%, HR0.82[0.66–1.02], p = .07). When comparing patients without CVD to those with one or three territories of CVD, the hazard ratio for the primary endpoint increased in unadjusted and adjusted models.Conclusions: The poorer outcomes in patients with established CVD are not mitigated by prolonged monotherapy with a potent P2Y12 inhibitor suggesting a greater need to focus on modifiable risk factors.


  • Clinical outcomes of complex lesions treated with an abluminal groove‐filled biodegradable polymer sirolimus‐eluting stent and durable polymer everolimus‐eluting stent

    by Yuichi Saito, Andreas Baumbach, William Wijns, Bo Xu, Henning Kelbæk, Ming Zheng, Marie‐Angèle Morel, Richard Anderson, Volker Schächinger, Alexandra Lansky, et al.

    Background: The Firehawk stent (Shanghai MicroPort Medical Group, Shanghai, China), a novel biodegradable polymer sirolimus‐eluting coronary stent has been evaluated in the randomized TARGET I trial in which low‐risk patients were enrolled with strict eligibility criteria. Recently, the TARGET All Comers study has shown similar results of the Firehawk compared to the XIENCE stent (Abbott Vascular, Santa Clara). However, clinical outcomes in high‐risk patients are unclear.Methods: The TARGET All Comer study was a randomized trial that assigned patients to either Firehawk or XIENCE implantation. This TARGET AC subanalysis sought to evaluate the 2 year clinical outcomes of patients according to two risk groups; patients meeting all inclusion criteria and no exclusion criteria of the TARGET I trial were classified as “low‐risk,” while their counterparts were classified as “high‐risk.” The primary endpoint was target lesion failure.Results: A total of 1,585 patients were included, of which 1,334 (84%) were classified as high‐risk. At 2 years, the high‐risk group had a significantly higher rate of TLF than the low‐risk group (9.5% vs. 3.6%, p = .003), mainly driven by increased target vessel myocardial infarction (6.3% vs. 2.4%, p = .02). The Firehawk and XIENCE had no significant differences in TLF among both low‐risk (3.1% vs. 4.2%, p = .66) and high‐risk (9.9% vs. 9.1%, p = .57) patients.Conclusions: High‐risk patients had worse clinical outcomes at 2 years in the TARGET All Comer study. Outcomes with the Firehawk were similar to the XIENCE stent among both low‐risk and high‐risk patients at 2 years.


  • Initial experience of a self‐expanding transcatheter aortic valve with an outer pericardial wrap: The United Kingdom and Ireland Implanters' registry

    by Cameron Dowling, Sami Firoozi, Vasileios Panoulas, Miles Dalby, Mavin N. Kashyap, Tito Kabir, Konstantinos Kalogeras, Mamta H. Buch, Richard Levy, Saqib Chowdhary, et al.

    Objectives: The United Kingdom and Ireland Implanters' registry is a multicenter registry which reports on real‐world experience with new transcatheter heart valves.Background: The Evolut PRO (Medtronic, Minneapolis, MN) transcatheter aortic valve is a self‐expanding transcatheter aortic valve with an outer pericardial wrap, designed to minimize paravalvular regurgitation.Methods: Between July 2017 and December 2018, clinical, procedural, and 30‐day outcome data were prospectively collected from all patients receiving the Evolut PRO valve across nine participating centers in the United Kingdom and Ireland. The primary efficacy outcome was the Valve Academic Research Consortium‐2 (VARC‐2)‐defined endpoint of device success. The primary safety outcome was the VARC‐2‐defined composite endpoint of early safety at 30 days.Results: A total of 317 patients underwent implantation. Mean age was 81.8 ± 6.4 years and Society of Thoracic Surgeons Predicted Risk of Mortality Score 5.5 ± 1.8%. Iliofemoral access was used in 99.1% of patients. Device success was 91.2%. Mean gradient was 7.6 ± 4.7 mmHg and effective orifice area 1.9 ± 0.7 cm2. The incidence of moderate paravalvular regurgitation was 1.7% and there was no severe paravalvular regurgitation. A new permanent pacemaker was implanted in 17.8% of patients without a pacemaker at baseline. Early safety was demonstrated in 92.7%. At 30 days, all‐cause mortality was 0.6%, stroke 3.8%, and major vascular complication 2.8%.Conclusions: Real‐world experience of the Evolut PRO transcatheter aortic valve demonstrated favorable procedural success, safety, valve function, and incidence of new permanent pacemaker implantation.